Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 14:17 PDT] Larimar Therapeutics, Inc. (NASDAQ:LRMR), Up By 100% ($2.38) From $2.38 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/23/2025 07:31 PDT] LRMR Expected to Trade Up After Bullish Patterns Develop
• [04/22/2025 12:42 PDT] Larimar Therapeutics, Inc. (NASDAQ:LRMR), Up By 100% ($1.88) From $1.88 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/16/2025 07:17 PDT] LRMR Expected to Trade Up After Bullish Patterns Develop
• [04/01/2025 11:07 PDT] Larimar Therapeutics, Inc. (NASDAQ:LRMR), Down By 100% ($2.37) From $2.37 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/19/2025 07:13 PDT] LRMR Expected to Trade Down After Bearish Patterns Develop
• [03/04/2025 10:29 PST] Larimar Therapeutics, Inc. (NASDAQ:LRMR), Down By 100% ($3.03) From $3.03 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/03/2025 07:42 PST] LRMR Expected to Trade Up After Bullish Patterns Develop